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Abstract
Bone is the second most transplanted organ, just after blood. It provides structural 
support, protection for organs and soft tissues. It holds some critical biological pro-
cesses such as the bone marrow blood forming system. It is responsible for storing and 
supplying minerals such calcium and phosphate. Bone is a connective tissue formed 
by two predominant phases: an inorganic phase containing mainly apatitic calcium 
and phosphate and an organic phase made of fibrous type I collagen. This natural 
biocomposite has many biological features such osteoconductivity, osteoinductivity, 
osteogenicity and is subject to a continuous remodeling process through osteoclastic 
and osteoblastic activities. In biomedical engineering, the restoration of damaged 
hard tissue with autologous bone is not always possible or even the best option. 
The development of some safe and low-cost alternatives such as biocomposites that 
mimic organic and calcified bone materials have shown very good results and offer 
an alternative to autologous bone implants. However, the mechanical properties of 
biocomposites still present a big challenge as a hard tissue substitute. This chapter 
reviews the properties of bone substitute materials chitosan and calcium phosphates, 
discusses strategies used in the treatment of calcified hard tissues as well as new 
approaches developed in this field.
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1. Introduction
Bone is the second most transplanted tissue in the world, second only to blood 
[1]. Hundreds of millions of people worldwide are affected by musculoskeletal 
conditions which are on the increase with aging population and lifestyle. Bone is a 
critical tissue within the vertebrates. It is a dynamic organ with many functions. It 
provides load bearing, body structural support onto which musculature is attached, 
protection for vital organs and soft tissues (brain, heart, lung, etc), and enables 
locomotion and motor functions. It is the host of important biological processes 
critical cells such as postnatal stem cell populations that support hematopoiesis, 
myelopoiesis, and skeletogenesis. Bone is also responsible for storing and supplying 
of minerals such as calcium and phosphate [2]. Native bone is a connective tissue 
made of two predominant components: a mineralized and an unmineralized phase. 
The mineralized inorganic phase contains mainly crystalline apatitic calcium phos-
phate (70%), water (20%), and the non-mineralized organic phase (10%) is made 
of fibrous type I collagen, proteins, polysaccharides and lipids (Figure 1) [3].
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This natural biological “composite” [4] has many biological features such 
osteoconductivity, osteoinductivity, osteogenicity and is subject to continuous 
remodeling and regeneration process through osteoclastic and osteoblastic activi-
ties. The hard tissues in vertebral is not uniform tissue it could be dense and hard 
like dental enamel and cortical bone or spongy and highly porous like a foam as the 
cancellous bone.
Hard tissue repair is a multifaceted, coordinated physiological process that requires 
new tissue formation and resorption, eventually returning the fractured bone, for 
example, to its original state. Bone has the capacity of regenerating itself, especially in 
noncritical size defects. However, large bone defects caused by trauma, injuries, tumor 
resections, infections, would not heal spontaneously, and would require a bone substi-
tute grafting material to fill the bony void for proper regeneration to take place [5].
The first documented bone transplant was performed in 1668 by a Dutch 
surgeon, Jacob van Meekeren, when he used dog cranium (xenograft) to repair a 
soldier’s skull defect. The success of the grafting technique was discovered later 
when the soldier came back asking for removal of the “dog bone,” because it cost 
him excommunication from the church. Meekeren discovered then that the bone 
healed so well it was impossible to remove the graft. The first human to human bone 
graft performed was in 1880 by Scottish surgeon William Macewan. He replaced 
the infected humerus of a 4- year-old boy with a tibia graft taken from a child with 
rickets [6]. The use of synthetic bone grafts could be traced back to as early as 1892 
when Dreesmann reported on the results of filling osseous defects with calcium 
sulfate [7]. Since then, hundreds of thousands of bone grafting surgeries have been 
performed on humans and animals.
In 1980, major health issues related to safety of bone donors (Aids and 
Hepatitis) has brought the associated problems of contamination and spread of 
dangerous diseases to the spotlight. Some years later, (1986) the discovery of the 
contagious pandemic bovine spongiform encephalopathy (BSE) and the porcine 
endogenous retrovirus (PERVs) [8], made more obvious the necessity of alterna-
tive safe bone substitute materials in bone transplant procedures. This provided 
a considerable boost to research and development in the usage of synthetic bone 
substitutes as a safe and an affordable alternative to natural bone materials. 
Since then, many technologies have been adopted and used to produce bone-like 
products with tailored biological, physical, and chemical properties, includ-
ing plasma projection [9], sol-gel [10], composites, foaming, nanotechnology, 
Figure 1. 
Cancellous and cortical bone microstructure.
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3D-printing techniques, additive manufacturing [8, 11] and some biological 
therapies that involve usage of growth factors, proteins, peptides, stem cells or 
gene therapies [12, 13].
Nowadays, many options are available to regenerate or replace bone in clinical 
conditions. The main clinical approach is using a natural or a man-made bone or bone 
induction materials (see Table 1). There are three categories of natural bone, a large 
family of synthetic bone substitutes and biological factors-based approaches. (Table 1).
In bone regeneration therapy, the gold standard has been the autograft (patient’s 
own harvested bone) [1, 9, 14]. However, autograft treatment is not always pos-
sible or even the best option. It is also limited by the volume of bone that can be 
harvested from the iliac crest and subsequently transplanted into the defect site. 
Furthermore, post-operative complications include morbidity at the harvest site, 
chronic pain, infection, local hematoma and, in some cases, remodeling issues of 
the implanted bone [8].
The established safety, efficacy, and abundance of supply of advanced synthetic 
bone-substitute materials made them stand as an attractive and effective alternative to 
the autogenous bone gold standard. On-going research in the field and a growing body 
of clinical data points to an even more promising future for these substitutes. Some 
calcium phosphate bioceramics, for example, display remarkable clinical performances 
and research and technological developments keep intensifying with the aim of bridg-
ing the gap to the ideal bone grafting material which would possess the three principal 
characteristics of the gold standard: osteogenicity, osteconduction and osteoinduction.
In human and animal medicine, orthopedic and dental surgeries, alloplastic 
biomaterials for hard tissue repair are divided in two categories that can be classi-
fied as per their biological responses:
i. The bio-inert materials category: They can be permanent or implanted 
for short-term and removed or replaced, like metallic dental or orthopedic 
implants. They are generally made of titanium, stainless-steel, nickel, zirco-
nia or made of synthetic polymers, e.g., polymethylmethacrylate (PMMA) 
or Polyether ether ketone (PEEK).
Category Advantage Limitations
Autografts No biological risk, osteogenic, 
osteoinductive, contain live 
cells
Limited supply Donor site, inflammation 
and chronic pain, site morbidity, Requires 
a second surgery, No mechanical
Allograft Greater supply compared to 
autograft tissue
• Reduced osteogenic, -Immune rejec-




Unlimited supply could be 
osteoconductive
• Reduced osteoinductive, osteogenic 
properties, Immune rejections, Disease 
transmission (Mad cow)
Synthetic (Alloplastic) Pure, Unlimited supply, 
Longer shelf life, tuneable 
properties
Do not have any biological factor,
Metal and polymeric 
based implants
Biocompatible, Load bearing 
applications
Not biodegradable, Bioinert, some toxicity 
(monomer, metal debris)
Cells, growth factors, 
BMP, PePgen, Ifactors
Natural Requires biomaterial carrier, Limited 
applications, side effects (BMP)
No mechanical
Table 1. 
Available therapies used to regenerate/support bone tissue.
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ii. The bioactive biomaterials: They are mostly resorbable at different levels. 
It is a large family of bone substitutes that vary in type and composition such 
as bioglass, calcium sulfate, calcium phosphate bioceramics (CaP), biopoly-
mers and biocements. They could also be in tunable forms such as powder, 
granules, blocs, paste or injectables. They offer a dynamic choice of material 
and applications.
In this chapter we will review some interesting development and advancement 
made in biomaterial sciences in regeneration of natural hard tissues through man 
made products. We will focus on the polysaccharide polymer, chitosan, similar 
to the organic phase of natural bone and cartilage and calcium phosphate based 
bioceramics, similar to the inorganic phase of natural bone. We will present some 
tested biocomposites formulations made out the combination of the two biomateri-
als to mimic the composition and structure of natural bone and discuss the success 
and limitation of the technology.
2. Chitosan biomedical and regenerative features
Many biomaterials are available in the market for medical, cosmetic, and phar-
maceutical applications. In tissue engineering, synthetic or natural biopolymers 
make one of the fastest growing niche segments of biomaterials. The growth is prob-
ably driven by the wide range of possibilities offered by their chemistry for different 
applications and the increasing demand of the biotechnology industry market.
After cellulose, chitin is the most abundant and beneficial structural 
non soluble organic biopolymers found on Earth. Chitin, a long polymer of 
N-acetylglucosamine, is the primary compound naturally found in the exoskeleton 
of arthropods such as crabs and shrimps, and in the cell membranes of fungi, 
yeasts, and other microorganisms. Deacetylation of some of acetylglucosamine 
units of chitin has brought a very interesting polysaccharide biopolymer to the 
biotechnology field, especially the biomedical area; chitosan (CS). CS is a polysac-
charide composed of successive acetylglucosamine and N-glucosamine units, where 
the number of N-glucosamine units is called the degree of deacetylation (DDA) 
[15] (usually 55% < DDA < 99%). CS macromolecules gained increasing attraction 
during the last three decades in research and industrial fields, especially in water 
treatment processes, pharmaceutical and biomedical engineering. Its chemistry 
with three reactive functional groups of amin/acetamido groups and primary and 
secondary hydroxyl groups allows for a large spectrum of possible chemical modi-
fications and substitutions of its functional groups (ex: OH, and NH2 by -COCH3, 
-CH3, -CH2COOH, SO3H, -PO(OH)2, etc) [16, 17]. This improves and creates addi-
tional functional properties and features and facilitates its adaptability to different 
applications such as antimicrobial agency in food processing and its packaging 
industries, as a fungicide, as a blood sugar and pressure reducing agent, as a dietary 
supplement. Other applications are also found in veterinary medicine, microbiol-
ogy, immunology, and agriculture, and most importantly, in highly innovative areas 
such as pharmaceuticals (e.g., drug delivery systems) and tissues/organs regenera-
tion medicine in the biomedical field [18].
The global chitosan market size was valued at USD 6.8 billion in 2019 and is 
expected to expand and reach USD 28.93 billion by 2027. After water treatment, the 
second largest market is the pharmaceutical and biomedical market [19].
In the chitosan manufacturing process, the degree of deacetylation (DDA) and 
the molecular weight (MW) are critical parameters, as the final properties and 
applications of the CS biomaterial will depend on it.
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Many parameters could affect the degree of deacetylation (DDA) and, 
consequently, the physical, chemical, and biological properties of chitosan. 
Parameters include the source raw material (animal, insect, fungi, mollusca, 
cephalopod, etc) [20] and processing conditions (pH, temperature, processing 
time). After manufacturing, batch parameters such as the degree of deacety-
lation (DDA), molecular weight (MW), molecular mass (MM), viscosity, 
solubility, pH, purity, protein content, endotoxin, ash content, contaminants 
should be carefully evaluated to ensure a safe and an adequate utilization.
Chitosan and chitosan derivative biopolymers were found to be non-toxic, 
biocompatible, osteogenic [21, 22] antibacterial, biodegradable, bioresorbable, 
antioxidant, immunoenhancing and anticancer [23]. In addition, they were found 
to promote cell adhesion, proliferation, and differentiation, which are important 
processes in tissue repair. It is, then, no coincidence that chitosan is one of the most 
extensively investigated polymers in tissue engineering to replace or restore the 
structure and function of damaged organs or tissues [24–34].
2.1 Chitosan and hard tissues
In the biomedical field, particularly in the tissue engineering domain, the main 
goal is to replace or substitute, repair maintain or improve tissue function through 
the use of isolated living cells, cells substitute tissue inducers on/or in a matrix to 
repair and regenerate tissue by combining engineering principles and life sciences 
[24, 25]. To reach that goal, there are critical properties that candidates biomaterials 
need to have. They are summarized in Table 2:
These imply that the biomaterial should allow the proliferation, adhesion 
and differentiation of the cells, the basic elements of any living tissue. Chitosan 
biomaterial can be processed in different forms such as film, mesh and fibers, 
freeze dried beads or scaffolds, as composite, as thermal, light, or chemical sensi-
tive injectable gel solution or crosslinked polymer. Alone or grafted with other 
biopolymers (e.g., alginate, polyvinyl alcohol, polyacrylic acid, etc) [27]. Among 
all the possibilities, researchers and physicians have to select the formulations 
that are most compatible with the targeted tissue environment and function. 
Characteristics Description of the characteristic
Biocompatibility They must be accepted by the receptor and must not lead to rejection 
mechanisms because of its presence.
Absorbability and degradability Absorbable, with controllable degradation and resorption rate to be the 
same as the in vitro and in vivo cell/tissue growth
Not to be toxic or carcinogenic Its degradation products cannot cause local or systemic adverse effect 
on a biological system
Chemically stable Chemical modifications not being present in a biological system 
implant or biodegradable in nontoxic products, at least during the 
scheduled time to regenerate tissue
Chemically adequate surface To have a chemically adequate surface for cell access, proliferation and 
cell differentiation
Adequate resistance and 
mechanical properties
Resistance and mechanical properties, superficial characteristics, 
fatigue time, and weight, according to the receptor tissue needs, as well
The proper design, size, and 
shape of the scaffolding
Which allows having a structure with properties according to the needs 
of the receiving tissue to regenerate or repair.
Table 2. 
Main characteristics that biomaterial should have.
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Hard tissues like bone and cartilage require some specific formulations, with 
specific chemical and physical properties to withstand the regeneration of the 
native hard tissues process.
2.1.1 Chitosan in cartilage tissue therapy
Osteoarthritis affects 7% of the global population. That is more than 500 million 
people worldwide. It is considered one of the critical causes of disability over the 
world population (28.) Cartilage, a connective tissue forming the skeleton, is a com-
plex tissue, not vascularized and is made of chondral cells that produce extracellular 
matrix proteins [29]. It is composed of a dense network of collagen fibers embed-
ded in a firm, gelatinous ground substance that has the consistency of plastic. This 
structure gives the tissue tensile strength, enabling it to bear weight while retaining 
greater flexibility than bone [30].
Cartilaginous connective tissues are highly involved into biomechanical func-
tion. They are subject to high load bearing stress. Critical size defects cannot heal 
on their own, so there is a need for tissular therapy to regenerate the cartilage 
tissue [28]. Different therapies are available, such as autograft (the gold standard) 
allograft (cardioviral tissue), mosaicplasty (autograft), autologous chondrocytes 
or tough tissue engineering procedures such as use biopolymer templates that are 
chitosan based.
chitosan has shown good success in regeneration of cartilage lesion, because 
it has structural similarity with various glycosaminoglycans found in articular 
cartilage [31].
A clinical study with 80 patients over a period of 1 and 5 years of a marketed 
thermosensitive hydrogel formulation BST-CarGel® (Smith & Nephew) has been 
reported. BST-CarGel® act as a scaffold and matrix that stabilize the blood clot in 
the cartilage lesion by dispersing a soluble and adhesive polymer scaffold contain-
ing chitosan throughout uncoagulated whole blood [32]. The gel is recommended 
for all synovial joints (knee, hip, and ankle) and on size defects ranging from 
0.3cm2 to 7cm2. The Product has two components: a soluble chitosan powder, and a 
solution of glycerophosphate salt. It is used arthroscopically using a microfracture 
techniques (bone marrow simulation). Patients were divided in two groups; one 
for the baseline where no product was used after the microfracture and the second 
was treated with the product mixed with autologous blood. The red viscous mixture 
was injected in the cartilaginous defect area to set. Following treatment periods, 
regeneration of cartilaginous tissue of 92.37% compared to 85.54% for baseline 
was observed after 12 months (Figure 2) and 93.79% vs. 86.96% respectively after 
5 years. The difference was statically significant [33].
In another study, layered highly porous nano structured 3D scaffold using 
chitosan and chondroitin sulphate was developed. It was loaded in vitro with 
bovine chondrocytes (BCH) and bone marrow derived stroma cells (hMSCs). The 
experiment was conducted for 21 days. It has shown that cells attached, proliferated 
and were metabolically active over the entire scaffold. Cartilaginous extracellular 
matrix (ECM) formation was further assessed, and results showed that glycos-
aminoglycan secretion occurred indicating the maintenance of the chondrogenic 
phenotype and the chondrogenic differentiation of bone marrow derived stromal 
cells. The mechanical properties were poor and not comparable to natural cartilage. 
The authors mentioned the need of improving the mechanical shortfall by adding 
growth factors, nanotubes, or crosslinked template polymers that would reduce the 
degradation rate [35].
With low mechanical performance and lack of clinical data for long periods 
(>5 years), it is difficult to fully assess the efficiency of the products.
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2.1.2 Chitosan in bone tissues therapy
Chitosan formulations were also used in bone tissue regeneration as a delivery 
system for bone morphogenic proteins, peptides, or growth factors for cells. The 
chitosan is tailored in general in the form of a 3D structure (e.g., freeze dried scaf-
fold and injectable gel), which is loaded with biological elements. In Table 3, we 
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Example of studies that have used chitosan-based formulation to treat bone defect.
Figure 2. 
Biopsy histology of the best repairs of the BST-CarGel and microfracture (MFx) groups at 13 months post 
treatment, the BST-CarGel biopsies show superior tissue quality and organization compared with the MFx 
biopsies [34].
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have reported some studies that have been performed with chitosan polymer or its 
derivatives to treat bone defects. Despite the good biological properties of chitosan 
formulations developed till now for hard tissues, the poor mechanical properties 
and lack of certain bioactivity proper to bone tissue such as osteoconduction, 
chitosan and derivatives are so far not the best clinical choice to treat bone defects.
Researchers have tried and are still trying to overwhelm the shortfalls. The most 
hopeful ones are those that combine chitosan-based formulations and synthetic 
inorganic biomaterial similar to the calcified phase of natural bone [42].
In the next section, we will review some of interesting options related to bone 
substitutes’ candidates that could be used along with chitosan to achieve a biomim-
icry of natural bone tissue.
3. Bone-like calcium phosphates
Bone and teeth are the hardest human tissues. Bone provides support and 
protection to organs. When skeletal system is damaged, an immediate fix is required 
to avoid any complications, physiological function and mobility impair and 
even death.
An ideal bone substitute should be biomechanically stable, able to resorb as 
natural bone within an appropriate time frame while new bone regenerate, exhibit 
osteoconductive (interconnected porous scaffold onto which bone cells can attach, 
migrate, differentiate, and grow new bone tissue). osteogenic and osteoinduc-
tive properties (ability to stimulate differentiation of a progenitor cells toward an 
osteoblast lineage) and provide a favorable environment for invading blood vessels 
and bone forming cell [43].
When it comes to bone substitution, autogenous bone is typically considered as the 
gold standard for bone defect regeneration since it is living tissue and contains osteo-
genic cells, still involves harvesting bone from one part of the patient’s body and put-
ting it in a damaged bone area. It was and still the method of choice in reconstructing 
bone either for dental or orthopedic applications. It provides perfect biocompatibility 
along with the body’s own growth factors and structural proteins. Because of limited 
supply, the need of a second surgery associated with site morbidity and infection risks, 
negative effect on the mechanics, autograft is not always possible or the best option.
Calcium phosphate (CaP) is the main constituent of inorganic phase of natural 
bone and teeth and it play essential roles in our daily lives. Damaged calcified natu-
ral tissues would be best repaired with something similar. CaP biomaterials are the 
most legitimate candidates when it comes to regenerate bone. They have been exten-
sively used for decade with great success in orthopedic and dental fields [44]. CaP 
bone substitutes materials are safe and efficient. They are biocompatible with bone 
tissues. When implanted they have the particularity to go over the same biological 
osteoclastic resorption and new bone regeneration processes as the natural bone. 
They are highly bio-similar to the inorganic phase of autologous bone tissue. Their 
resorbability and solubility depend in general in their ratio Ca/P (Table 4) empirical 
formulations were proposed to describe the mineral composition of natural bone 
[45]. The chemical formula of Calcium Phosphate materials eq. (1) is shown below: 
 ( ) ( ) ( )1/28,31,7 4 4 3 34,3 1.7 0,31.7Ca PO HPO orCO OHor CO  (1)
Actually, mineral bone composition is more versatile, it has many other minor 
chemical elements such: Mg, Sr., Si, F, Na, and others (Table 4).
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The composition and crystallinity of bone tissues depends on many parameters 
(location: cortical, cancellous, dental enamel, dentine, the age, biological metabo-
lism, etc).
Many studies have reported development of CaP products that would be used as 
potential bone substitutes. In the Table 5, a list of the main most popular products 
used in the development or formulation of CaP biomaterials.
One of the furthermost interesting CaP biomaterials are the osteoconductive 
biphasic calcium phosphate (BCP) containing Hydroxyapatite (HA) and Beta TCP. 
These two phases have different resorption rates. HA (less soluble) will provide 
short- and long-term physical stability to the bone defect and scaffold for bone 
ingrowth, whereas Beta TCP (more resorbable) will provide locally Ca and phos-
phate ions to regenerate new bone and activate the osteogenesis process [46]. To 
enhance the physical, physiological and/or therapeutical properties, CaP biomateri-
als could be easily assorted with polymers, drug, proteins, Growth Factors, cells, 
blood cells, bone marrow and even autologous bone tissue.
CaP biomaterials are relatively easy to make osteoconducteurs by different 
methods, to mimic the trabecular structure of natural bone (Figures 3 and 4).
% Element Enamel Dentine Bone HA
Ca 37,6 40,3 36,6 39
P 18,3 18,6 17,1 18,5
CO2 3,0 4,8 4,8 /
Na 0,7 0,1 1,0 /
K 0,05 0,07 0,07 /
Mg 0,2 1,1 0,6 /
Sr 0,03 0,04 0,05 /
Cl 0,4 0,27 0,1 /
F 0,01 0,07 0,1 /
Ratio Ca/P 1,59 1,67 1,65 1,67
Crystallinity good low low good
Table 4. 
Chemical composition of calcified hard tissues vs. stochiometric synthetic Hfydroxyapatite (HA).




CaHPO4·2H2O; DCPD 1.00 88
Octocalcium phosphate CasH2(PO4)6·5H2O;OCP 1.33 8.1
Hydroxyapatites Ca10(PO4)(OH)2; HA 1.67 9.4
α-Tricalcium phosphate α-Ca3(PO4)2; α-TCP 1.50 2.5
β-Tricalcium phosphate β-Ca3(PO4)2; β-TCP 1.50 0.5
Biphasic Calcium phosphate xβ-Ca3(PO4)2 + yCa10(PO4)6(OH)2; 
BCP
1.50–1.67 0.3–0.5
Tetracalcium phosphate Ca4(PO4)2O; TTCP 2.00 0.7
Table 5. 
Short list of calcium phosphates with biological interest.
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New developed formulations were found to have some outstanding properties 
similar to biological growth factor in autologous bone such bone morphogenic pro-
teins (BMPs). They are osteoinductive. The osteoinduction is trigged either by the 
addition of chemical elements such silicates ions (Actifuse bone graft, by Baxter) or 
by tailored sub-micron surface topography and porosity [47] that has the capability 
to induce bone formation in ectopic or heterotopic location such in muscle or under 
skin. (Figures 5 and 6). The mechanism through which a Ca-P graft mediates an 
osteoinduction in the host bed is still an active subject of research.
This approach has more benefit. It is less expensive and safer than the BMPs 
therapy that has limitations (e.g.: not recommended in bone joints or small bones, 
serious complication, and side effects (cancer, unpredictable ectopic bone growth, 
neurological impairment, fertility problem …) [48].
A study conducted by Van Dijk et al., showed that in spine fusing in ovine 
model, formulation of osteoinductive submicron surface topography of BCP bone 
graft (Magnetos) outperforms Bioglass and monophasic Tricalcium phosphate 
CaP bioceramics (Vitoss) mixed with Bioglass. The induced bone growth was 
found similar when using autologous bone (Figure 5) [48]. Unlike the other 
natural substitutes, there is no risks of incompatibility, allergy, or transmission of 
diseases.
Figure 3. 
Optical microscopic pictures (x8) of natural cancellous bone (left) and synthetic osteoconductive bioceramics 
(BCP 50–50%) (right, porosity >70%, Biomatcan).
Figure 4. 
Histological picture of Osteoconductive bone graft implanted in rabbit tibia bone after 12 weeks. Pores are filled 
with new bone (Osteoconduction). BV: Blood vessels, NB: New bone, I: Implant (x50) (Biomatcan).
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We can confirm that synthetic CaP biomaterials are safe and a reliable alterna-
tive for autograft or allograft. With a history of safety and effectiveness in clinical 
both human and animal health, they are gaining more attention and started to be 
considered the new gold standard in bone regeneration therapy.
4. Biocomposites: Chitosan-CaP bioceramics
Many researchers have worked on development of biocomposites containing CS 
[49–55] and CaP biomaterials. If the biological properties were improved in some 
cases, the mechanical properties still not comparable to natural bone. In this section 
we are going to report some testing and results on the developed biocomposites: 
Figure 5. 
Posterolateral fusion on ovine model: Histomorphometry diagrams of bone performed on low-magnification 
micrographs of histologic sections. Data are presented as area%, in mean and SD. ★, significantly different 
from BG and TCP/BG (P < 0.001). (P < 0.005) and TCP/BG. AB: Autograft bone; BCP < μm, biphasic 
calcium phosphate with submicron topography; BG, bioglass; TCP, tricalcium phosphate. [47].
Figure 6. 
Ct-scan of heterotopic implantation of Osteoinductive BCP (50–50%) in mice model, noticeable increase 
(10.6%) of implant size after 40 days. (Biomatcan).
Chitin and Chitosan - Physicochemical Properties and Industrial Applications
12
An injectable bone graft formulation and hardening injectable bone cements. The 
mechanical properties were evaluated in both of cases.
4.1 Bone graft biocomposites
The bone graft was prepared as follow: A solution of chitosan (1,7%) (DDA 
83% ± 3%, supplied by Biomolecules and Organic Synthesis Laboratory, Ben 
M’Sick University, Casablanca) was prepared in diluted chloric acid solution 
(0.2 N). The chitosan was dissolved under ultrasonic agitation. Disodium 
glycerophosphate solution (0.5 N) was added slowly under agitation at low 
temperature. The pH was maintained between (6.5–7). The chitosan solutions 
were then autoclaved. Porous Biphasic calcium phosphate bioceramics (BCP) 
(50%Beta TCP-50%HA, porosity = 76%, Biomatcan) with average granules size 
of 135 microns was added slowly and gently homogenized. It was found dur-
ing the preliminary tests, that the best formulation that preserve homogeneity 
and injectability have a ratio of BCP comprising between 35% and 50%. Low 
concentration led to aggregation of the granules and high concentration affects 
the injectability and the structural stability of the biocomposites. The obtained 
products were kept at cold temperature till use. The mechanical properties of the 
obtained biocomposites were measured at physiological temperature (37 oC) with 
rheometer (Brookfield DV3T). The obtained results are reported in the table and 
figures bellow (Table 6, Figures 7 and 8).
In this case we notice that the increases of the BCP mass in the chitosan solution 
increase the mechanical properties of mixture. This increase is not linear. The maxi-
mum is obtained for L/S = 40%. Over this limit the biocomposite is less injectable 
and less elastic. 0.4% of BCP represent the maximum load for this formulation with 
optimal mechanical properties.
BCP (%) 0 0.36 0.40 0.44 0.5
Chitosan solution (%) 1.7 1.7 1.7 1.7 1.7
Elastic modulus (Kpa) 1.8 3.8 14.2 5.2 2.8
Time (min) 27 115 40 63 62
Table 6. 
Eleastic moduls of biocomposite bone graft with different BCP.
Figure 7. 
Elastic modulus of biocomposites formulations (KPa, 37°C).
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4.2 Injectable bone substitute material- biocements
The biocements are made by mixing solid (S) and liquid phases (L) they are 
known to harden in certain conditions, the mechanical properties depend on the 
solid and liquid compositions. They are used in bone augmentation situations like 
joint fixation, maxillofacial surgeries, and others. We have tested biocomposites 
made by two different chitosan solutions.
4.2.1 Self-hardening biocomposites
These materials are made out of a grafted chitosan mixed with Alpha PTC 
bioceramics fine powder. The biocomposites has the advantage that when it is mixed 
with the CS solution it forms an injectable paste that turns to rubber-like material. 
It should provide a good initial mechanical stability for the bone defect and the 
implant. The hardening of the biocomposites occurs progressively over time. The 
biocomposites was prepared as follow:
Grafted chitosan solution: a mPEG-grafted-chitosan [49] transparent and homo-
geneous gel was prepared from a liquid chitosan aqueous solution (chitosan 2.0% 
w/v, pH < 6) and Monomethoxypolyethyleneglycol-N-hydroxysuccinimidylsuccinate 
(mPEG-suc- NHS). The obtained polymer solution was mixed with fine powder CaP 
ceramic powder (PTC alpha, Ca/P = 1.50, D50 = 4microns, Biomatcan). The Liquid/
powder ratio (L/S) varies from 0.4, to 0.6. The biocomposites cement pastes were 
injected in a rubber made cylindrical molds (6 mm in diameter x 12 mm height). The 
elastic silicone-like articles were demolded and stored at 37°C in humid atmosphere 
for 24 h to harden. The solid blocs were matured in Simulated Body Fluid (SBF) 
solution at 37°C for 3, and 7 days. Then washed with cold distilled water and dried 
at 40oC for 24 h. The obtained biocomposites articles were mechanically tested 
(Zwick Z010 mechanical testing machine, with a crosshead speed of 1 mm/min). 10 
specimens were tested for each test formulation. The measured compressive strength 
(MPa) for different ratio L/S is reported in Table 7.
4.2.2 Self hardening CaP biocements
The biocements are made with crosslinked CS formulations and without chi-
tosan solution were prepared and compared side by side. Chitosan (83% ± 3 DDA) 
Figure 8. 
Representative example of rheological test obtained at 37°C.
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was dissolved in 1%HCl). The pH was maintained 6.7 to 7 with Sodium glycero-
phosphate (Sigma Aldrich). The solid phases were selected from different sources 
of CaP material. The tricalcium alpha (alpha)TCP and Hydroxyapatite (HA) 
supplied by Biomatcan, tetra calcium phosphate (TTCP, Cambioceramics, NL), 
Brushite (DCPD) and monocalcium phosphate (MCPM) from Sigma-Aldrich.
The biocomposites were prepared by mixing powder and solutions with prede-
termined ratio L/S. The paste was handled as mentioned before. When the cements 
harden, the cylindrical blocs were put in phosphate buffer saline solution at 37°C, 
pH 7.4 for 24 hours, then washed with cold water and dried at 40°C for 24 hours. 
The formulations and obtained results are summarized in Table 8.
The results of the mechanical tests on both formulations show that the addition 
of mPEG- grafted-chitosan solution or crosslinked chitosan solution decreases 
dramatically the mechanical properties of self-herding biocements. It could be 
explained by the effect of chitosan on the CaP crystal growth during maturation of 
the biocements, or by the heterogenous structure of the biocements, where chitosan 
polymer creates some discontinuity in the physical structure. Moreover, the shrink-
age of the chitosan network during the drying process could induce a distortion of 
the article volume thus reducing its mechanical properties. In-vivo testing would be 
the best approach to assess the mechanical properties of such formulations.
5. Conclusion
In conclusion we have presented some works done related to the development 
of chitosan, CaP biomaterials that mimic the composition of natural bone. Despite 
the proven biological benefits and the huge number of research, publications and 
patents done on the use of chitosan in medical field and especially in hard tissues 
replacement, there is a big discrepancy between research, commercial and market 
reality. Less than handful products are marketed mainly for cartilage repair.









αTCP-DCPA 1.33 0.5 17.3 + 3.1 7.9 + 2.2 54%
αTCP-MCPM 1.37 0.72 12.8 + 3.9 11.8 + 1.6 7%
αTCP-HA 1.52 0.5 29.0 + 4.9 11.3 + 4.8 61%
αTCP-HA-
MCPM
1.55 0.46 12.7 + 3.9 11.2 + 1.5 11%
TTCP-MCPM 1.66 0.55 8.3 + 1.0 2.9 + 0.4 65%
TTCP-DCPA-
MCPM
1.50 0.60 6.8 + 2.5 2.2+ 0.5 67%
Table 8. 
Compressive strength comparison of biocement formulations prepared with water vs. 1 of chitosan solution.
Ref 0.4 ml/g 0.5 ml/g 0.6 ml/g
3 days 23.22 + 3.58 8.51 + 1.76 7.73 + 1.95 5.51 + 1.30
7 days 29.68 + 4.23 9.82 + 0.26 5.69 + 0.94 4.04 + 1.66
Table 7. 
Compressive strength (MPa) obtained for different bone cement with modified chitosan solution after 3 and 
7 days of maturation (Ref = PTC alpha with water only, L/S = 0.5).
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The principal obstacles are proper to the material itself and processing. No 
validated manufacturing process, variability in the raw material, the formulations 
developed up to date have low mechanical properties, regulatory burden associated 
with the endotoxin content that require additional steps and control in the manu-
facturing process, the sterilization that affect the polymer, the storage, shelf life and 
stability conditions especially for the liquid and gel formulations. However, some 
new technologies have been tested to solve some of these problems, such plasma 
sterilization that delivers free endotoxin chitosan raw material [56]. It is still at early 
stage and need to be validated technically and economically at large scale. Other 
improvements still have to come before chitosan and derivative become attractive 
solution in bone tissue regeneration for the bioindustry players.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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